Abstract
Introduction

Drug discovery is an interdisciplinary, complex, time consuming and expensive process. It is widely admitted that the pharmaceutical industry now spends far more on research and development but produces fewer new molecules than 20 years ago. The PriceWaterhouseCoopers Pharma report for 2005 stressed that the pharmaceutical industry needs to find means to improve the efficiency and effectiveness of drug discovery and development. It projected that in silico methods will become a dominant tool to address this issue, from drug discovery to marketing. Recently, advances in computational techniques and hardware have enabled in silico methods to speed up lead identification and optimization.
Up till now, these techniques have contributed to the design of about 50 compounds that entered clinical trials, some of which are now FDA approved [1] . [1] . Those methods are detailed below. Fig. 1 shows the successful docking of the Cilengitide molecule on the ␣V␤3 integrin surface realized with EADock [2] . Pioneered during the early 1980s [3] , docking remains a vigorous research area, and is now among the most useful tools for in silico drug design and a primary component in many drug discovery programs [4] [5] [6] [7] [8] .
As of today, in silico drug design should not be seen as a 'voilà' technique able to suggest directly a small number of compounds with a high affinity and selectivity for the targeted macromolecule, along with favourable pharmacokinetic and pharmacodynamic properties, and using only the three dimensional (3D) structure of the target as a starting point. It rather consists of a systematic use of a wide range of different computational tools aiming, for instance, at improving the knowledge about the target-ligand interactions (molecular docking), increasing the yield of molecules screening by focusing the search on compounds more likely to bind the target (virtual high-throughput screening [vHTS]) or even suggesting new potential lead compounds (fragment-fragment-based ligand design [FBD])
Docking
Molecular docking tries to predict the native position, orientation and conformation (so-called native pose, or native binding mode) of a small-molecule ligand within the binding site of a targeted macromolecule. By providing the basic understanding of the interactions that are taking place between the ligand and its receptor, docking opens the door to affinity estimation prior to synthesis, as well as to ligand optimization techniques. As an example,
Docking [5] . The most widely used are AutoDock [9, 10] , Genetic Optimisation for Ligand Docking (GOLD) [11, 12] , FlexX [13] /FlexE [14] , DOCK [3, 15] and Internal Coordinate Mechanics (ICM) [16] /ICM-flexible receptor docking algorithm (IFREDA) [17] . Table 1 [23] . These programs vary in the way they handle poses, in their operators and scoring functions. The reader is referred to relevant papers for a more detailed description of these methods. [25, 26] [30, 31] .
Scoring functions
The scoring functions typically implemented in protein-ligand docking can be divided into three major categories [5]: knowledge-based, empirical and force-field-based scoring functions. Knowledge-based scoring functions use inter-atomic interaction potentials obtained by a reverse-Boltzmann analysis of the occurrence of different atom-atom pair contacts in known experimental complex structures
Performance
The performance of docking programs is generally assessed through re-docking calculations. First, hundreds to few thousands of experimentally determined representative ligand-protein complexes are collected, like the Ligand-Protein Database [32] , the Astex/Cambridge Crystallographic Data Centre (CCDC) [33] and Astex/Diverse [34] [37, [41] [42] [43] . [47, 48] . This strategy can also be used as a filter before applying a structure-based vHTS, so that only 1-10% of the initial database has finally to be docked [46] .
Virtual high throughput screening
Structure-based vHTS
Structure-based vHTS is probably the most straightforward application of docking algorithms. It consists of using a molecular docking program to determine the binding mode on the protein target for an entire database of existing or virtual compounds [44, 46, 49] . The bound conformations are used to approximate the binding free energy or the related affinity of the compound. [50] [51] [52] [53] [54] [55] , the outcome in terms of new compounds reaching the clinics might be seen as rather disappointing [56, 57] . [58] . [59] or experimentally using nuclear magnetic resonance (NMR) or X-ray crystallography [60] . This review will focus on in silico approaches. [66] .
Then, the most promising compounds are retained for further experimental testing. The most widely used docking programs for vHTS are DOCK, FlexX, Glide, GOLD and AutoDock. The size of the libraries used in such an approach ranges from hundreds of thousands to a few million compounds, limiting the time available for each docking to a few minutes or less. The size of the database is a trade off between the number of molecules that can be treated in a reasonable amount of time, and the chemical space that is desirable to cover. Despite the steady improvement of computer hardware, the conformational sampling is, therefore, very limited and vHTS suffers from a lot of false negatives. Despite the vast amount of resources invested in HTS and vHTS, and several successful studies
In silico fragment-based drug design
Since a few years, FBD has become an attractive alternative to experimental or virtual HTS. Contrarily to HTS, where complete molecules are screened for activity, FBD aims at building new ligands piece-by-piece by connecting small and well-chosen compounds that bind into separate binding pockets, close enough to be chemically linked in their relative favourable positions
When tested experimentally, hit molecular fragments exhibit generally only weak affinities, with IC50 in the order of 1 mM to 30 M. However, they provide interesting starting points for follow-up strategies trying to connect several of them to give new efficient lead compounds. Fragment-based design can be performed in silico
Theoretical advantages of FBD
This number is nearly of the same order of magnitude of what is tested with HTS, but covers a much vaster part of the chemical space. Second, FBD leads to higher hit rates. This is illustrated by the fact that the probability of a bad ligand-protein interaction
increases exponentially with the size and complexity of the molecule [67] . As a consequence, the probability that small and simple molecules bind to the protein, even with a low affinity, is much higher than for HTS-size compounds. This probability climbs up to 30% to 40% for simple fragments [67] . This supports the use of molecular fragments to anchor the drug design process rather than complex and large molecules. (Fig. 2) , with better chances of favourable pharmacokinetic properties [57] .
Finally, FBD leads to molecules with a higher ligand efficiency. HTS chemical libraries are composed of complex molecules originally developed for other purposes than binding to the current target. As a consequence, even a HTS hit is expected to form suboptimal binding interactions with the target. On the contrary, due to its size, a high proportion of the atoms in a fragment hit are directly involved in protein-binding interaction. Their optimization has thus a better probability to lead to more efficient and therefore smaller drugs
Interestingly, the binding free energy of a molecule resulting from an optimal linking of two fragments is expected to be lower, thus more favourable, than the sum of the free energies of binding of the two isolated fragments [68] (see Fig. 3 [70, 71] to thousands of fragments [72] . Several approaches are available to automatically decompose molecules into rigid fragments [73, 74] . Several methods have been developed for in silico FBD (see Table 2 ), which differ in the building blocks used to construct the ligands (atoms or fragments), the target constraints applied (ligandor receptor-based), the strategy used to sample the chemical space (depth first [59] , breadth first [59] , MC, EA), the structural sampling (mainly growing, linking and random structure mutations) and the scoring function used to rank the putative ligands. Among the most representative methods, one can find LUDI [75] , Multicopy Simultaneous Search (MCSS) [76] /HOOK [77] , PRO_LIGAND [78] [81, 82] . The latter are called the secondary constraints.
The linking approach (Fig. 2B ) starts with the placement of building blocks at key interaction sites of the receptor. This can be done by the fragment-based design software itself, or using a dedicated software like MCSS [76] , Solvation Energy for Exhaustive Docking (SEED) [83] or EADock [2] . The latter is particularly suited for the fragment-based approach since, thanks to its cluster-based sampling algorithm and its universally applicable scoring function, it is able to both map fragments favourable positions and dock complete molecules [2] . The positioned fragments are then automatically connected to each other using linkers, resulting in several complete molecules that satisfy all key interaction sites. On the contrary, the growing procedure (Fig. 2C) [5] .
Several studies have illustrated the ability of vHTS to suggest putative lead compounds, and help its experimental counterpart by reducing drastically the number of molecules that will be effectively tested. However, despite the large efforts that have been deployed, the outcome in terms of new compounds reaching the clinical trials might be seen as rather disappointing [56, 57] . 
